Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.
about
Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterialsInsights into the Nanog gene: A propeller for stemness in primitive stem cellsHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsAutochthonous mouse melanoma and mammary tumors do not express the pluripotency genes Oct4 and NanogPathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progeniesMicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers.Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expressionAssociation between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.BMI-1, a promising therapeutic target for human cancer.Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.Development of animal models underlining mechanistic connections between prostate inflammation and cancerMarked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Expression array analysis of the hepatocyte growth factor invasive program.Current status in cancer cell reprogramming and its clinical implications.The SDF-1/CXCR4 axis induces epithelial–mesenchymal transition in hepatocellular carcinoma.Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis.Neural stem/progenitor cells react to non-glial cns neoplasms.Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies.Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.
P2860
Q26860518-9BE90E08-012A-4041-9E55-F5768A7E5B0CQ28073695-858C7DDC-1A32-4F9E-9CC9-CA5AF34B98BAQ28393898-0070FBF4-9B9D-4515-8F7A-B4AB1A3DE149Q28487410-828184BD-4024-45D7-BE8A-150593C10AB5Q31049380-BBF05D5A-49B2-4FCF-B9C7-1B2C3FFDC1E0Q34154782-A3E47E66-6124-4D3A-A15D-0A0C5E3F2D39Q34469245-4A937E44-A708-4EAE-846E-A451EED12151Q34766747-206CE675-15BF-469F-873B-AA920BB47381Q35551899-4FED5437-2061-4208-9611-E317C5C60FA3Q35870390-A44359D2-65F6-434B-B54F-1B6B092B842CQ36043833-BDF560AE-7166-4A6D-800B-0F7AE2B86EB5Q36297949-5E644DFC-D10F-4062-B897-B1BF3444DE5AQ36718905-07CD543A-13D7-4AA0-BAC0-D45631F5D533Q36746688-D8FC0F3A-8C32-4E5A-8034-A28CA13EA18EQ37136259-F625C4D8-C941-467F-BF42-9082C6049902Q38180344-B1FEC0FA-6372-4573-83DF-0829A8A5DA0AQ38847534-14FB4CF4-8B5B-448D-A20E-7DD8AE68413AQ38952695-0F848082-C6F0-4C89-BC56-477CC7643EC0Q39012765-DCB8EF4E-BB8C-493A-B473-72A4E4884F1CQ39264728-74C91DE7-7DF9-4001-BA8C-73B1730610BFQ39372549-DE463299-10A1-46A6-B564-FB628FBC8F00Q40289695-A31BE432-0B43-4406-BC06-4D866A9693CEQ41613206-58343C6E-3379-469B-86B9-483EA2C1C787Q41873088-2D6732F4-75C7-43A8-94D4-F71BFE1DC682Q41990493-88250C31-E4A5-4799-9451-2D1E08320C37Q46416599-D601E013-6E19-4648-B226-77CF48DF6584Q47106447-B2ED4894-692B-4A2D-A414-F6650CC274F6Q47935277-5323EFB3-790A-4E9C-A04B-D10B2C0D29F3
P2860
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Frequent gene products and mol ...... ising multitargeted therapies.
@ast
Frequent gene products and mol ...... ising multitargeted therapies.
@en
type
label
Frequent gene products and mol ...... ising multitargeted therapies.
@ast
Frequent gene products and mol ...... ising multitargeted therapies.
@en
prefLabel
Frequent gene products and mol ...... ising multitargeted therapies.
@ast
Frequent gene products and mol ...... ising multitargeted therapies.
@en
P2860
P1433
P1476
Frequent gene products and mol ...... ising multitargeted therapies.
@en
P2093
Murielle Mimeault
Surinder K Batra
P2860
P2888
P304
P356
10.2119/MOLMED.2011.00115
P407
P577
2011-05-20T00:00:00Z
P5875
P6179
1068965399